** Shares of drug developer Cardiff Oncology rise 33.2% to $3.25 premarket
** Co announces positive initial data from its mid-stage trial testing its experimental cancer drug, onvansertib, in combination with standard-of-care treatment in patients with a type of colorectal cancer
** Co says the combination treatment showed a 64% objective response rate $(ORR.AU)$ in patients who were dosed with 30 mg of the drug vs a 33% ORR in patients who received standard of care alone
** ORR is the proportion of patients whose tumors reduced in size or disappeared over a predefined amount of time
** Co says 30 mg dose demonstrated a higher ORR compared to 20 mg dose, with deeper tumor reduction in patients who received the 30 mg dose
** The drug was well-tolerated and there have been no major or unexpected toxicities observed - CRDF
** Co says additional clinical data is expected in the first half of 2025
** Up to last close, stock up 64.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。